BioNTech Archives

News and Trends 21 Sep 2016

German Biotech allies with Genentech in battle for Cancer Vaccine

BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The German biotech has partnered with American giant Genentech in a massive deal with almost €300M upfront. Europe’s largest private biotech, BioNTech, has partnered up with Genentech to produce individualized mRNA-based cancer therapies. The collaboration aims […]

September 21, 2016 - 3 minutesmins - By Evelyn Warner

biontech mrna vaccine cancer immunotherapy nature

News and Trends 2 Jun 2016

First All-Cancer mRNA Vaccine that Works Published in Nature

Update (05/07/2017): BioNTech has published new results in Nature revealing a strong immune response in all 13 patients treated with its personalized mRNA cancer vaccine, strengthening its potential to become a universal cancer vaccine. Originally published on 02/06/2016 BioNTech and its academic partners have published in the well-known publication Nature, describing the first clinically applicable and systemic […]

June 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 11 May 2016

German mRNA specialist moves into Animal Health in collaboration with Bayer

BioNTech is joining its mRNA technology with Bayer’s expertise in veterinary applications in a new collaboration – to develop first-in-class vaccines for animals. Based in Mainz (Germany), BioNTech is the largest private Biotech in Europe. Along with its CAR-T and TCR programmes, BioNTech is developing mRNA therapies – a promising field in medicine. These include immunotherapies for […]

May 11, 2016 - 2 minutesmins - By Denise Neves Gameiro

In Depth 5 Jan 2016

Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?

What if we could send the body an instruction to produce its own drug? That’s what messenger RNA (mRNA) could achieve. A whole new area of therapeutics could be opened. Let’s try to get an overview of how… So for those who don’t know what a mRNA is, here are some basics. This diagram below […]

January 5, 2016 - 7 minutesmins - By Jerome Topsent

News and Trends 12 Nov 2015

EU’s Largest Private Biotech talking on the Future of mRNA Therapies

Today is the 3rd International mRNA Health Conference in Berlin. I jumped in the metro to go there and interview the most successful people of the field… We first interviewed Sean Marett, COO of BioNTech. This German Biotech is the largest private Biotech in EU and so far counts over 400 employees…BioNTech also recently signed […]

November 12, 2015 - 1 minutemin - By Philip Hemme

News and Trends 7 Nov 2015

What Happened this Week? BIO-Europe 2015, mRNA deal, Cellectis CAR-T

Monday: The French Scientist Who Also ‘Discovered’ CRISPR is Finally Recognized with a Prize too Tuesday: €100 Million Investment Round Prepares CureVac For Vaccine Expansion Wednesday: €1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech Thursday: Damn, that was BIO-Europe 2015 in Munich! Friday: Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on […]

November 7, 2015 - 1 minutemin - By Philip Hemme

News and Trends 4 Nov 2015

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Sanofi is now the latest Biotech lining up to partner with BioNTech from Mainz (Germany), for license of their mRNA Immuno-oncology platform in a€1.37Bn long-term development deal. Novel mRNA targets in Immuno-onology is a top-shelf cancer R&D area, with Germany’s CureVac also attracting another €100M yesterday for their mRNA platform (which targets lung and prostate […]

November 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 14 May 2015

Eli Lilly signs a €250M deal with BioNTech for new Cancer Immunotherapies

Using immunotherapy to treat cancer is one of the hottest trends in healthcare research right now. The latest collaboration in the field has been announced by Eli Lilly and the German Biotech BioNTech. They will identify and validate novel tumor targets and their corresponding T cell receptors (TCRs) in one or more types of cancer. Cancers figure […]

May 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 20 Oct 2014

European’s First Personalized Vaccines to Treat Brain Cancer

A novel concept of fully personalized therapeutic cancer vaccines, called Glioma Actively Personalized VAccine Consortium (GAPVAC), has been moved into the clinic. It is the first european approval for such a technology. The project is lead by two german Biotech companies Immatics biotechnologies and BioNTech, and received a €6 million grant from European Union. The German National Authorities has approved the […]

October 20, 2014 - 3 minutesmins - By Julie Lellouche

csm ganymed start bilder04 new 7ec1db04d4

News and Trends 2 Oct 2014

BioNTech and Ganymed Pharmaceuticals Open One of the Largest Research Facilities in Germany

BioNTech AG and Ganymed Pharmaceuticals AG, two leading German biotechnology companies, announced today the joint- opening of a new headquarters and research facility of approximatively 10,000 square-meters. The new facility brings together 300 employees and is located close to academic institutions (Johannes-Gutenberg University), hospitals (University Medical Center) and cancer research institutions such as the leading translational oncology […]

October 2, 2014 - 2 minutesmins - By Julie Lellouche

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us